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Despite remarkable therapeutic improvement in multiple myeloma (MM), prognosis is very poor once patients become refractory to or ineligible for proteasome inhibitors and immunomodulatory drugs. Accordingly, new drugs are clearly needed for this patient population, and extensive efforts are leading to a new breed of antimyeloma drugs. 1 In this regard, the PD-1/PD-L1 axis has recently emerged as a master immune checkpoint that controls antitumor immune responses against many neoplasms. Namely, PD-L1-expressing tumor cells in the tumor microenvironment engage PD-1 on tumor-infiltrating T lymphocytes to repress antigen-driven activation. 2 PD-L1 expression is also considered an adaptive resistance mechanism as PD-L1 is induced on tumor cells when under immune attack in response to immune-stimulating cytokines such as interferons. 2 Importantly, antibodies to PD-1 and PD-L1 have already shown clinical activity in melanoma, 3 renal-cell carcinoma, 4 non-small-cell lung cancer, 2 refractory Hodgkin lymphoma and bladder cancer. Predictive correlates of response mainly based on the expression of PD-L1 and the abundance of T lymphocytes are being intensively investigated. 3, 4 In MM, clinical trials targeting the PD-L1/PD-1 axis are already being conducted, 5 even though only two (discordant) studies have investigated expression of PD-L1 on CD138 + PCs: one showed that PD-L1 is commonly present (although at low levels), 6 whereas the other report found PD-L1 to be positive in only~25% of patients. 7 Accordingly, it could be the case that not all MM patients are equally likely to benefit from therapeutic targeting of the PD-1/PD-L1 axis, at least when used in monotherapy strategies. Discordant results have also emerged regarding levels of PD-1 expression on T and Natural killer (NK) cells from MM patients. [8] [9] [10] In vitro experiments showed increased MM cell death after enhancement of T-cells 9 and NK-cells 8 with anti-PD-1 monoclonal antibodies (mAb), whereas only two in vivo studies have been performed; both evaluated anti-PD-L1 mAb in the 5T33 mouse model either after autologous (syngeneic) stem-cell transplantation plus administration of a cell-based vaccine or after lymphodepleting irradiation, showing survival improvement. 9, 11 Here, we sought to define the expression of PD-L1 and PD-1 in clonal PCs as well as T and NK cells on bone marrow (BM) aspirates from monoclonal gammopathy of undetermined significance (MGUS) and MM patients at diagnosis, after treatment (minimal residual disease (MRD)) and upon relapse by using standardized multidimensional flow cytometry (MFC). We then evaluated efficacy of anti-PD-1 mAb therapy in a syngeneic mouse model after intravenous injection of 5TGM1 secretory MM cells.
We prospectively studied 107 patients, including 20 MGUS and 87 MM (47 at diagnosis, 25 after treatment to monitor MRD and 15 at relapse); normal BM samples were obtained from healthy volunteers or individuals undergoing orthopedic surgery (n = 9). All samples were collected after receiving informed consent, in accordance with local ethics committees and the Helsinki Declaration.
MFC was performed on EDTA anticoagulated BM samples, immunophenotyped using a direct 8-color immunofluorescence stain-and-lyse technique, with the following combination of monoclonal antibodies (PacB/OC515/FITC/PE/PerCP-Cy5.5/PE-Cy7/APC/APCH7): CD45/CD138/CD38/CD56/PD-1/CD19/PD-L1/CD3 and HLA-DR/CD27/CD45RA/CCR7/PD-1/CD25/CD8/CD4. In the first combination, we measured PD-L1 (Biolegend, San Diego, CA, USA; clone 29E.2A3) expression on normal and clonal PCs after careful discrimination according to aberrant phenotypic profiles, 12 as well as the percentage of PD-1 + NK-cells (SSC lo CD45 + CD56 + CD19 -CD3 -) using the Infinicyt software (Cytognos, Salamanca, Spain). In the second combination, we determined the percentage of PD-1 + CD4 and CD8 T-cells, as well as the distribution of PD-1 + versus PD-1according to peripheral maturation stage and activation status. Data acquisition was performed for ⩾ 10 6 leukocytes/tube in a FACSCantoII flow cytometer (BD Biosciences, San Jose, CA, USA) by using FACSDiva software (BD Biosciences; version 6.1). Instrument performance was monitored daily with cytometer setup beads (BD Biosciences) and rainbow 8-peak beads (Spherotech, Inc.; Lake Forest, IL, USA) after laser stabilization, following the EuroFlow guidelines; sample acquisition was systematically performed after longitudinal instrument stability was confirmed. Flow data were analyzed with Infinicyt software (Cytognos).
We established mouse 5TGM1 myeloma cells from the transplantable mouse 5T33 myeloma of spontaneous origin. 13 5TGM-1 cells (0.75 × 10 6 per mouse) were intravenously inoculated via the tail vein into 6-to 8-week-old female naive C57BL/ KaLwRijHsd mice. 14 Immediately after tumor cell inoculation, mice were randomly assigned for treatment with control rat immunoglobulin G antibody (Sigma-Aldrich, St Louis, MO, USA) or anti-PD-1 mAb (RPMP1-14 BioXcel). Doses were 100 μg of mAb every other day for three doses on days 3, 6, and 9 after tumor cell inoculation. Mice were checked twice weekly for survival or signs of terminal disease. Weight loss appeared only when mice reached a terminal status and could not be attributable to potential side effects. We assessed 5TGM1-specific monoclonal paraprotein (IgG2bκ) in sera prepared from whole blood obtained by submandibular vein puncture of tumor-bearing mice under light methoxyflurane-induced anesthesia. We assayed mouse IgG2bκ levels by using a specific in-house sandwich enzyme-Accepted article preview online 17 March 2015; advance online publication, 17 April 2015 linked immunosorbent assay as previously described. 14 PD-L1 and PD-L2 were measured by MFC on 5TGM1 myeloma cells with or without IFNγ stimulation.
We first analyzed expression of PD-L1 on BMPCs. Consistent with previous observations, 6,7 PD-L1 was present at very low levels on PCs from healthy individuals (Figure 1a and Supplementary Figure 1A) . Levels of PD-L1 expression on clonal PCs from newly diagnosed MGUS and MM patients were not significantly increased as compared with normal PCs from healthy individuals (1731 vs 1029 mean fluorescence units (MFI) P40.05). These results contrast with previously reported data 6,7 that focused on the percentage of PD-L1 + PCs rather than on the MFI of a surface antigen with a remarkable homogenous and unimodal pattern of expression. The lack of differences between MGUS and MM also differs from previous observations, 6, 7 which could be explained not only by the different methods used to quantify PD-L1 levels (percentage of positive cells vs MFI units), but also because herein we measured PD-L1 expression on specifically selected clonal PCs ( Supplementary Figure 2) . Previous studies did not distinguish between polyclonal and clonal PCs, which coexist in MGUS patients. 12 To assess the potential impact of measuring PD-L1 expression on total PCs (including both normal and clonal) versus selected clonal PCs, we compared PD-L1 levels on total PCs from MGUS (n = 20) and MRD-positive patients (n = 19) versus PD-L1 expression specifically measured on clonal PCs from the same patients. Interestingly, significant differences were noted between PD-L1 levels on total PCs vs selected clonal PCs (medians of 1477 vs 1681 MFI units, respectively; P = 0.009), stressing the importance of a careful phenotypic evaluation of unambiguously identified tumor cells in BM samples where normal and tumor cells coexist within the PC compartment (for example, MGUS or MRD-positive patients). Interestingly, we observed increased levels of PD-L1 on persistent MRD-positive clonal PCs as compared to normal PCs from healthy individuals (2876 vs 1029; P = 0.05). In fact, approximately half (10/19) MRD-positive patients were in the top quartile of PD-L1 expression (median and quartiles defined according to PD-L1 expression observed in selected clonal PCs from all disease stages).
PD-1 expression was absent on CD56 + CD3 -NK-cells (data not shown) and was found on T-cells ( Figure 1b ) in similar median percentages between controls and newly diagnosed MGUS and MM patients' CD4 and CD8 T-cells (P40.05). In BM samples obtained from MRD-positive (but not MRD-negative) and relapsing MM patients, there was a significant increase in PD-1 expression ( Figure 1b) among both CD4 and CD8 T-cells. We then investigated the phenotypic features of CD4 and CD8 PD-1 + versus PD-1 -T-cells; the former displayed significantly increased expression of HLA-DR, as well as clear predominance of antigen experienced over naive T-cells ( Supplementary Figure 3) . Thus, it could be hypothesized that if PD-1 recognizes its ligand (PD-L1) on the surface of clonal PCs, such T-cells would be restrained in their functions. Conversely, blockage of the PD-1/PD-L1 axis could help to restore the function of tumor-antigen-experienced T-cells. 11 Other immune check points (for example, CTLA-4, TIM-3 and BTLA) were found to be similarly distributed among MM patients PD-1 − and PD-1 + T-cells ( Supplementary  Figure 4) , and their contribution should be considered while designing immunotherapeutic approaches including combinations. 15 According to the (i) the lack of significantly increased PD-L1 levels on clonal PCs from MM patients, (ii) the significantly increased PD-1 expression on T-cells from MRD-positive and relapsing MM patients, and (iii) the lack of in vivo data on antimyeloma activity of specific PD-1 blockage, we decided to investigate the efficacy of anti-PD-1 therapy in a C57BL/KaL-wRijHsd syngeneic mouse model. After demonstrating the presence of PD-L1 (in the absence of PD-L2; Supplementary  Figure 5 ) on 5TGM-1 MM cells (Figure 2a) , and PD-1 on a median of 41% and 5.5% of mice CD4 and CD8 T-cells (Figures 2b and c) , we then randomized two cohorts of mice intravenously injected with 5TGM-1 secretory MM cells to receive a course of control or anti-PD-1 mAb. The therapeutic effect of anti-PD-1 mAb was shown by a significantly superior survival for mice treated with anti-PD-1 (P = 0.0007; Figure 2d ). In parallel, serial serum M-protein measurements in additional cohorts of five mice per group ( Figure 2e ) showed that anti-PD-1 significantly reduced tumor growth (1/slope: 101 vs 58; P = 0.0024).
In summary, we showed that PD-L1 is variably expressed in clonal PCs of newly diagnosed MGUS and MM patients. By contrast, MM patients with persistent MRD (but not those MRD negative) after treatment as well as at relapse showed upregulation of PD-L1/PD-1, suggesting that it can operate as an immune checkpoint in the tumor microenvironment. As blocking PD-1 prolonged survival in disseminated myeloma-bearing mice, our results support therapeutic investigation of anti-PD-1 in MM; that notwithstanding, given the patterns of expression observed herein, it could be envisioned that not all patients would equally benefit from PD-1 blockade. Accordingly, we postulate that predictive correlates of response to anti-PD-L1 or anti-PD1 blockade based on the characterization of both tumor and effector lymphocytes will be of paramount importance in MM as reported in other tumors. Here, we have found that patients with persistent MRD after conventional therapy might represent an interesting cohort to investigate therapeutic interventions targeting the PD-1/PD-L1 axis. CD4 T-cells CD8 T-cells Figure 2 . In vivo antimyeloma effect of anti-PD-1. We intravenously injected C57BL/KaLwRijHsd syngeneic mice with 5TGM-1 that were consistently positive for PD-L1 (a) secretory multiple myeloma (MM) cells and after 7 weeks randomized mice to receive vehicle (n = 4) or anti-PD-1 (n = 4). PD-1 expression was assessed on CD4 (b) and CD8 (c) T-cells of C57BL/KaLwRijHsd mice with or without 5TGM-1 MM cells (no significant differences between the two mice subgroups). (d) Overall survival Kaplan-Meier curves from a separate experiment identically performed as in panel A with 12 and 11 mice per group, as indicated in the graph legend. We used the log-rank test to estimate statistical significance of differences between survival curves (P = 0.0007). (e) Kinetics of serum M-component measured in the two cohorts on days 7, 14 and 21. Serum M-component was significantly reduced in mice treated with anti-PD-1 (1/Slope: 101 vs 58; P = 0.0024).
